SFB 1365: Renoprotection

肾损伤，即使表面上看起来恢复了，也会显著降低预期寿命。我们的跨学科研究联盟旨在识别和靶向肾衰竭的常见途径。慢性肾脏病（CKD）对公共卫生的威胁迅速增加，CKD的发病率每十年翻一番。目前，超过10%的普通人口和超过30%的老年人受到影响。急性肾损伤（阿基）也很常见。五分之一的住院成人和三分之一的住院儿童会发生阿基。我们的跨学科研究联盟包括内科医生，外科医生，生理学家，药理学家，分子生物学家，遗传学家，物理学家，解剖学家和放射学家，都专注于肾保护。我们将共同对分离的细胞，组织制备和动物模型（包括酵母，斑马鱼，啮齿动物和基因工程猪）进行基础研究，并将结果转化为患者护理。这些研究工作将伴随着在临床环境中对阿基和CKD患者进行标准化识别和评估的策略，从而为持续实施提供基础。我们拥有德国最大的CKD和各种其他肾脏疾病患者队列。通过创造这种跨学科的临界质量，CRC 1365将解开并靶向肾损伤的特定途径。例如，我们将使用高分辨率晶体学照亮受体和通道结构，最先进的技术将使我们能够表征这些结构。我们将推进模式生物更接近人类的环境，即，从斑马鱼到啮齿动物和猪。人类肾脏微血管在全球范围内由拟议的CRC专门研究。我们广泛的模型谱的最终转化将依赖于最新的MRI技术来跟踪不同的缺氧区域和炎症过程。我们的愿景是通过建立CRC 1365 Renoprotection作为一个全面的跨学科网络来减少肾脏疾病的负担，以促进针对CKD共同途径的定制治疗策略。在未来12年内，我们将确定和表征CKD发展和进展的潜在途径，建立新的治疗靶点，并启动临床试验。

Damage to the kidney, even in spite of apparent recovery, markedly reduces life expectancy. Our interdisciplinary research consortium aims to identify and target common pathways to kidney failure. Chronic kidney disease (CKD) poses a rapidly increasing public health threat, with the incidence of CKD doubling each decade. Currently, more than 10% of the general population and over 30% of all elderly are affected. Acute kidney injury (AKI) is likewise very common. One in five hospitalized adults, and one out of three in-patient children, develop AKI. Our interdisciplinary research consortium involves internists, surgeons, physiologists, pharmacologists, molecular biologists, geneticists, physicists, anatomists, and radiologists, all focusing on renoprotection. Together, we will perform basic research on isolated cells, tissue preparations, and animal models including yeast, zebrafish, rodents, and genetically engineered swine, and translate the outcomes to patient care. These research efforts will be accompanied by strategies for standardized identification and assessment of patients with AKI and CKD in the clinical setting, thus providing the basis for sustained implementation. We have at our disposal the Germany-wide largest patient cohort with CKD and various other renal diseases. By creating this interdisciplinary critical mass, CRC 1365 will unravel and target specific pathways of renal damage. For instance, we will illuminate receptor and channel structures using high-resolution crystallography, and state-of-the-art techniques will allow us to characterize these structures. We will advance model organisms much closer to the human setting, i.e., from zebrafish to rodents and swine. Human renal microvessels are world-wide exclusively investigated by the proposed CRC. Ultimate translation of our broad model spectrum will rely on the latest MRI technology to track distinct hypoxic regions and inflammatory processes.Our vision is to reduce the burden of kidney disease by establishing CRC 1365 Renoprotection as a comprehensive, interdisciplinary network to foster tailored therapeutic strategies aiming at the shared routes to CKD. Within the next 12 years, we will Identify and characterize pathways underlying CKD development and progression, establish new therapeutic targets, and initiate clinical trials.